Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study. (PubMed, Lancet Neurol) - Sep 25, 2026 - "Lecanemab treatment was associated with dynamic, multidirectional changes across plasma biomarkers of Alzheimer's disease pathology, with partial normalisation of amyloid and tau biomarkers alongside abnormal concentrations of inflammatory and neurodegeneration-related biomarkers (eg, TREM2 and NPTXR), which might reflect an immune response to amyloid plaques and effects of treatment on neuronal and synaptic processes distinct from amyloid clearance. These divergent trajectories suggest that different biomarkers could eventually serve different clinical purposes, such as monitoring treatment response or informing patient prognosis, although further validation is needed."
Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • APOE • GFAP • MAPT • NEFL • TREM2
|
|
Aditi Gupta; Alex Roussak; Anna Hofmann; B Joy Snider; Carlos Cruchaga; David M Holtzman; Inez Oh; John Budde; John C Morris; Joseph Lowery; Katherine Gong; Madeline Paczynski; Menghan Liu; Nicholas Sykora; Randall J Bateman; Rui Mu; Steven Funk; Suzanne E Schindler; Tammie L S Benzinger; William J B Powell; Yike Chen; Ying Xu; Yuchen Cheng; Yunchang Xie; Zachary Posey
|